Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China.
Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shannxi, 710032, China.
Anticancer Agents Med Chem. 2023;23(1):94-104. doi: 10.2174/1871520622666220519100054.
Melanoma is a highly invasive and metastatic malignant tumor originating from melanocytes and is associated with a poor prognosis. Surgical resection and chemotherapy are currently the main therapeutic options for malignant melanoma; however, their efficacy is poor, highlighting the need for the development of new, safe, and effective drugs for the treatment of this cancer.
To investigate the effects of alantolactone (ALT) on the proliferative, migratory, invasive, and apoptotic ability of malignant melanoma cells and explore its potential anticancer mechanism.
Melanoma cells (A375 and B16) were treated with different concentrations (4, 6, 8, and 10 μmol/L) of ALT, with DMSO and no treatment serving as controls. The effects of the different concentrations of the drug on cell proliferation were assessed by crystal violet staining and CCK-8 assay. The effects on cell migration and invasion were detected by wound healing and Transwell assays, respectively. Flow cytometry was used to evaluate the effects of the drug on apoptosis and the cell cycle. ALT target genes in melanoma were screened using network pharmacology. Western blotting was used to measure the expression levels of the proliferation-related protein PCNA; the apoptosisrelated proteins Bax, Bcl-2, and caspase-3; the invasion and metastasis-related proteins MMP-2, MMP-7, MMP-9, vimentin, E-cadherin, and N-cadherin; and the canonical Wnt signaling pathway-related proteins β-catenin, c-Myc, and p-GSK3β. In addition, an l model of melanoma was established by the subcutaneous injection of A375 melanoma cells into nude mice, following which the effects of ALT treatment on malignant melanoma were determined in vivo.
Compared with the controls, the proliferative, migratory, and invasive capacity of ALT-treated melanoma cells was significantly inhibited, whereas apoptosis was enhanced (P<0.01), showing effects that were exerted in a dose-dependent manner. The expression levels of the pro-apoptotic proteins Bax and caspase-3, as well as those of the interstitial marker E-cadherin, were upregulated in melanoma cells irrespective of the ALT concentration (P<0.05). In contrast, the expression levels of the anti-apoptotic protein Bcl-2, the proliferation-related protein PCNA, and the invasion and metastasis-related proteins MMP-2, MMP-7, MMP-9, N-cadherin, and vimentin were downregulated (P<0.05). The network pharmacology results indicated that GSK3β may be a key ALT target in melanoma. Meanwhile, western blotting assays showed that ALT treatment markedly suppressed the expression of β-catenin as well as that of its downstream effector c-Myc, and could also inhibit GSK3β phosphorylation.
ALT can effectively inhibit the culture viability, migration, and invasion of A375 and B16 melanoma cells while also promoting their apoptosis. ALT may exert its anti-melanoma effects by inhibiting the Wnt/β-catenin signaling pathway. Combined, our data indicate that ALT has the potential as an effective and safe therapeutic drug for the treatment of melanoma.
黑色素瘤是一种起源于黑色素细胞的高度侵袭性和转移性恶性肿瘤,预后较差。手术切除和化疗是目前治疗恶性黑色素瘤的主要治疗方法,但疗效不佳,需要开发新的、安全有效的药物来治疗这种癌症。
探讨冬凌草甲素(ALT)对恶性黑色素瘤细胞增殖、迁移、侵袭和凋亡能力的影响,并探讨其潜在的抗癌机制。
用不同浓度(4、6、8 和 10 μmol/L)的 ALT 处理黑色素瘤细胞(A375 和 B16),以 DMSO 和无处理作为对照。用结晶紫染色和 CCK-8 测定不同药物浓度对细胞增殖的影响。用划痕愈合和 Transwell 测定分别检测细胞迁移和侵袭的影响。用流式细胞术评估药物对细胞凋亡和细胞周期的影响。用网络药理学筛选黑色素瘤中的 ALT 靶基因。用 Western blot 测定增殖相关蛋白 PCNA 的表达水平;凋亡相关蛋白 Bax、Bcl-2 和 caspase-3;侵袭和转移相关蛋白 MMP-2、MMP-7、MMP-9、波形蛋白、E-钙黏蛋白和 N-钙黏蛋白;以及经典 Wnt 信号通路相关蛋白β-catenin、c-Myc 和 p-GSK3β。此外,通过将 A375 黑色素瘤细胞皮下注射到裸鼠中建立黑色素瘤模型,在体内确定 ALT 处理对恶性黑色素瘤的影响。
与对照组相比,ALT 处理的黑色素瘤细胞的增殖、迁移和侵袭能力明显受到抑制,而凋亡增强(P<0.01),呈剂量依赖性。无论 ALT 浓度如何,促凋亡蛋白 Bax 和 caspase-3 的表达水平以及间质标志物 E-钙黏蛋白的表达水平均升高(P<0.05)。相反,抗凋亡蛋白 Bcl-2、增殖相关蛋白 PCNA 以及侵袭和转移相关蛋白 MMP-2、MMP-7、MMP-9、N-钙黏蛋白和波形蛋白的表达水平下调(P<0.05)。网络药理学结果表明 GSK3β 可能是黑色素瘤中 ALT 的关键靶点。同时,Western blot 检测表明,ALT 处理显著抑制β-catenin及其下游效应物 c-Myc 的表达,并能抑制 GSK3β磷酸化。
ALT 能有效抑制 A375 和 B16 黑色素瘤细胞的培养活力、迁移和侵袭,同时促进其凋亡。ALT 可能通过抑制 Wnt/β-catenin 信号通路发挥其抗黑色素瘤作用。综上所述,数据表明 ALT 具有作为治疗黑色素瘤的有效和安全治疗药物的潜力。